Planned in-vivo testing by NIH/NIAID is great news
Post# of 72440
(Total Views: 807)
Posted On: 03/15/2023 11:31:25 AM
Planned in-vivo testing by NIH/NIAID is great news as government entities fund ongoing research. Effectiveness in 13 of 19 priority fungal infections should elevate the priority of the Brilacidin approval process. Synergistic use with other drugs could spark a Big-Pharma partnership.
===========================
“that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.”
“Brilacidin has now exhibited varying degrees of inhibition against 13 of 19 “priority” fungal pathogens identified by the World Health Organization in need of novel treatments.”
“USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi. Additive effects were similarly observed in Brilacidin combinations with voriconazole and geldanamycin against A. fumigatus, as well as with posaconazole against Mucorales. Separate in vitro laboratory testing evaluating Brilacidin in combination with other conventional antifungals – including caspofungin, fluconazole, posaconazole, amphotericin B and micafungin – demonstrated additive or synergistic inhibition of fungal growth.”
===========================
“that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.”
“Brilacidin has now exhibited varying degrees of inhibition against 13 of 19 “priority” fungal pathogens identified by the World Health Organization in need of novel treatments.”
“USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi. Additive effects were similarly observed in Brilacidin combinations with voriconazole and geldanamycin against A. fumigatus, as well as with posaconazole against Mucorales. Separate in vitro laboratory testing evaluating Brilacidin in combination with other conventional antifungals – including caspofungin, fluconazole, posaconazole, amphotericin B and micafungin – demonstrated additive or synergistic inhibition of fungal growth.”
(11)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼